GILD 3Q18 results—HCV sales=$902M,-10% QoQ: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2373553 http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDEyNDE4fENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636759229545616779 3Q18 US HCV sales were $487M, -10% QoQ; 3Q18 ex-US HCV sales were $415M, -10% QoQ (see slide #25).